Latest Headlines

Latest Headlines

Sanofi, Merck to split up their long-standing vaccines JV in Europe

Sanofi Pasteur MSD, the European vaccines joint venture between pharma giants Sanofi and Merck, has been around for 22 years. But now, the pair has decided that's long enough.

S. Korea's GeneOne joins with Inovio on Zika virus vaccine preclinical work

Seoul-based GeneOne Life Sciences is working with Inovio Pharmaceuticals on preclinical efforts to develop a vaccine to the Zika virus in a second collaboration between the firms that also joined hands on a Middle East respiratory syndrome, or MERS, vaccine effort last year.

Asia included in Zika virus warning zone as drugmakers ponder vaccines

The Zika virus currently on a rampage in the Americas could easily spread to Asia where other mosquito-borne diseases like dengue fever and malaria are already endemic and drugmakers in the region, and elsewhere, are racing to come up with a vaccine.

Japan scolded for lag in vaccinations

Japan's ban on the combination vaccine for mumps, measles and rubella in routine immunizations, a cumbersome bureaucracy, and a lack of vaccine coverage in the country's healthcare program are putting the nation at risk, various officials and researchers claim.

Vaccines present 'biggest breakthrough' in animal health: Report

Global health and trade organizations have been pushing for increased access to veterinary drugs, with groups such as HealthforAnimals and the World Organization for Animal Health laying out potential solutions. But vaccines could have the greatest impact on animal health, with experts in a new report calling vaccination the "biggest breakthrough" in the field in the past 100 years.

Don't split up the dynamic duo of GSK's vaccines and drugs, vax chief says

Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But take it from GSK vaccines chief Moncef Slaoui--splitting apart is a bad idea, at least on the vaccines front.

GSK's Slaoui sees 'major' vaccine market disruption for Merck as shingles candidate progresses

SAN FRANCISCO-- Look out, Merck & Co.: GlaxoSmithKline expects its shingles candidate, Shingrix, to be a "major market disrupter" when it wins approval.

India lands $500M for vaccination program from Gavi alliance

Geneva-based Gavi, the global vaccine alliance funded by the Bill and Melinda Gates Foundation and other donors, has pledged $500 million over the next 5 years to support India's country-wide immunization program.

Japan's Kaketsuken at center of major vaccine, blood product records fraud

For more than 40 years, a longtime Japanese drugmaker apparently carried out an elaborate subterfuge worthy of a grand conspiracy theory. Chemo-Sero-Therapeutic Research Institute, known as Kaketsuken, acknowledged violations and a massive cover-up lasting for decades.

GSK beefing up vaccine business in India

GlaxoSmithKline is making a move to beef up its vaccine business in India and has started the ball rolling with a price cut on its pneumonia vaccine Synflorix and set the stage for two product launches in 2016, according to a report by the  Business Standard.